MedTrace Logo

Relative Bioavailability Study

NCT01602887 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-11-12

No results posted yet for this study

Summary

This is a BA study comparing the bioavailability of two new capsule formulations and one solution formulation to the isethionate capsule used in phase 1 and 2 trials in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

PD-0332991

isethionate hard capsule, 125 mg, single dose

DRUG

PD-0332991

freebase hard capsule with a "small" particle size, 125 mg, single dose

DRUG

PD-0332991

freebase hard capsule with a "large" particle size, 125 mg, single dose

DRUG

PD-0332991

oral solution, 50 mg, single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01602887 on ClinicalTrials.gov